Issue of Equity

THIS ANNOUNCEMENT (THE "ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (596/2014/EU) ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION, AS PERMITTED BY MAR. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

DXS INTERNATIONAL PLC

Issue of Equity

DXS International plc ("DXS", the "Company"), the digital clinical decision support company, is pleased to confirm that, following its announcement on 19th February 2020, the Company has today completed the placing and subscription of ordinary shares to raise just over GBP 1 million. The Company confirms that a total of 12,675,000 new ordinary shares were issued and admitted to trading today and that following the fundraising, the Company has a total of 48,256,416 ordinary shares in issue.

David Immelman, CEO of DXS International plc commented: "I'm delighted to have received this supportive funding at a high growth phase in the Company's development as DXS moves into scale up and further commercialisation."

The Directors of DXS International plc accept responsibility for this announcement

Contacts:

David Immelman   (Chief Executive)

DXS International plc
01252 719800

-systems.co.uk 



Corporate Advisor



 
 
City & Merchant Limited

David Papworth



 
020 7101 7676



 



Corporate Broker and sole broker to the Placing



 
 
Hybridan LLP

Claire Louise Noyce



 
020 3764 2341



 

Notes to Editors

About DXS:

DXS International plc presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

EN
26/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DXS International PLC

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Research: DXS International PLC

Good Afternoon, DXS International PLC (AQSE:DXSP) announced Interims to 31 October 2025. We have published research on this which is attached and a snapshot of the research is below.

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Small Cap Feast: 28 January 2026

28th January 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: Following a Reverse Tak...

 PRESS RELEASE

DXS International plc (AQSE: DXSP): Half-year Financial Report

DXS International plc (AQSE: DXSP): Half-year Financial Report DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2025. H1 2025 Financial highlights: Core recurring revenue model remains resilient. Revenue decreased by 2.6% to £1,684,712 (H1 2024 - £1,730,829) in the six months to 31 October 2025 ("Period"). Administration costs decreased by 5% in the Period (H1 2024 -£87,474)Loss afte...

 PRESS RELEASE

DXS International plc (AQSE: DXSP) Update on Cyber Security Incident

DXS International plc (AQSE: DXSP) Update on Cyber Security Incident 24 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Update on Cyber Security Incident The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, would like to provide an update on the security incident that affected its office servers, which was reported via RNS on 18 December. The incident has been contained, and DXS remains vigilant by implementing additional monitoring and security measures.  The Director...

 PRESS RELEASE

DXS INTERNATIONAL PLC (AQSE: DXSP) Result of AGM

DXS INTERNATIONAL PLC (AQSE: DXSP) Result of AGM 19 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Result of DXS AGM 2025 The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that all resolutions put to shareholders at the Company's Annual General Meeting ("AGM") held yesterday were duly passed. All resolutions were passed on a poll and the votes received from shareholders on each resolution put to the AGM are set out below. ResolutionVotes For *...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch